Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)
PHARMASCIENCE INC
N06AX16
VENLAFAXINE
75MG
CAPSULE (EXTENDED RELEASE)
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG
ORAL
100/500
Prescription
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0131294001; AHFS:
APPROVED
2007-08-02
_VENLAFAXINE XR (venlafaxine hydrochloride) _ _Page 1 of 84 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR VENLAFAXINE XR Venlafaxine Hydrochloride Extended Release Capsules Extended Release Capsules, 37.5 mg, 75 mg and 150 mg venlafaxine (as venlafaxine hydrochloride), Oral Antidepressant / Anxiolytic PHARMASCIENCE INC. 6111 Royalmount Ave, Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control Number: 265116 Date of Initial Authorization: July 20, 2012 Date of Revision: November 8, 2022 _VENLAFAXINE XR (venlafaxine hydrochloride) _ _Page 2 of 84 _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 11/2022 7 Warnings and Precautions, 7.1 Special Populations, 7.1.1 Pregnant Women 04/2020 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ..................................................................................................................... 4 1.1 Pediatrics ............................................................................................................... 4 1.2 Geriatrics................................................................................................................ 4 2 CONTRAINDICATIONS........................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.1 Dosing Considerations ............................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment Adults ....................... Կարդացեք ամբողջական փաստաթուղթը